Related Experiment Video

Updated: Jun 2, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges

B Ryan Phelps1, Natella Rakhmanina

  • 1Division of Infectious Disease, Childrens National Medical Center, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

Paediatric Drugs
|April 20, 2011
PubMed

Insights

Antiretroviral (ARV) therapy is effective for pediatric HIV, but challenges remain in drug delivery and palatability for children. Further research is needed on pediatric pharmacokinetics and fixed-dose combinations.

Area of Science:

  • Pediatric infectious diseases
  • Pharmacology
  • Global health

Background:

  • Antiretroviral (ARV) therapy demonstrates high efficacy in treating pediatric Human Immunodeficiency Virus (HIV) disease.
  • Successful management of pediatric HIV relies on affordable, child-friendly, and easily administered ARV drugs.
  • Global access to pediatric ARV therapy has significantly increased.

Purpose of the Study:

  • To review the pharmacokinetics of ARV agents in pediatric HIV-infected patients.
  • To discuss practical challenges in current pediatric ARV formulations.
  • To highlight the need for improved drug delivery and palatability in pediatric HIV treatment.

Main Methods:

  • Literature review of ARV pharmacokinetics in pediatric populations.
  • Analysis of challenges associated with pediatric ARV drug formulations.
  • Discussion of developmental changes in drug pharmacokinetics from infancy to adolescence.

Main Results:

  • Limited data exist on developmental changes in ARV drug pharmacokinetics in children.
  • Current ARV formulations present challenges, including poor palatability of liquids and difficulties with crushing tablets.
  • Issues arise with the use of both adult and pediatric fixed-dose combinations for pediatric patients.

Conclusions:

  • Despite progress, significant challenges persist in delivering palatable and effective ARV drugs to children.
  • Understanding pediatric pharmacokinetics is crucial for optimizing ARV therapy across different age groups.
  • Improvements in formulation and delivery are essential for successful long-term management of pediatric HIV.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...